Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other hand, the loss of function in certain kinases has been identified as a ...

Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP ...

Actuate Therapeutics, Inc. announced that data on their investigational drug elraglusib, designed to treat advanced salivary gland carcinoma by inhibiting glycogen synthase kinase-3 beta (GSK-3β ...

Factors like β-catenin, BDNF, GSK-3β, and mTOR are all candidates for mediating this switch. Could trauma 'prime' the brain to respond differently to drugs? Does Nk3R antagonism only work when ...

Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat ...

Elraglusib is designed to inhibit GSK-3β, targeting pathways involved in tumor growth and resistance to chemotherapy, while potentially enhancing anti-tumor immunity. The company cautions that ...

Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional ...

We were encouraged by the response rate among the non-Adenoid Cystic Carcinoma (ACC) population with nuclear GSK-3β overexpression given this difficult to treat and rare cancer type", said Dr ...